Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Aterian Inc (ATER) vs Mesoblast Limited (MESO) Price & Performance

Aterian IncTrade
Mesoblast LimitedTrade

Price performance (Past 24H)

Key statistics

Aterian Inc vs Mesoblast Limited — how do they compare? Aterian Inc trades at $0.48 (market cap $5.32M), while Mesoblast Limited trades at $16.68 (market cap $2.21B). The key difference: Mesoblast Limited is far larger — about 415.4× Aterian Inc's market cap, and Mesoblast Limited is trading nearer its 52-week high, Aterian Inc nearer its low. Which is the better fit depends on your goals.

ATERMESO
Market Cap
$5.32M$2.21B
Sector
Consumer CyclicalTechnology
52-Week High
$1.39$20.96
52-Week Low
$0.36$12.88
Enterprise Value
$5.90M$2.21B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Aterian Inc

No Aura AI signal available yet.

Mesoblast Limited

MESO trades at $15.94, up 2.05% today, with a bullish technical signal from moving averages but mixed oscillators. The company reported Ryoncil net revenues of $36 million for Q2 2026 (GlobeNewsWire, July 29, 2026), showing commercial traction, yet fundamentals reveal a net loss of -$102.14 million in 2025 with a negative net margin. Valuation metrics include a P/S of 30.52 and P/B of 3.76, indicating high growth expectations.

Outlook hinges on Ryoncil's expansion and pipeline progress, but risks include sustained losses and regulatory hurdles. Analysts are cautiously optimistic with 45% buy ratings, yet the stock faces volatility from earnings misses and high cash burn.

Returns comparison

Trailing returns across standard periods

About Aterian Inc

Aterian Inc is a technology-enabled consumer products company. Its product categories include home and kitchen appliances, kitchenware, environmental appliances (dehumidifiers and air conditioners), beauty-related products, and consumer electronics. It has various owned and operated brands include Vremi, Healing Solutions, Xtava, TRUWEO, Spiralize, Pohl+Schmitt, and RIF6. The company generates revenue through the online sales of various consumer products that are sold online.

Read more on ATER

About Mesoblast Limited

Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.

Read more on MESO